174 related articles for article (PubMed ID: 38114742)
1. Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.
Harter MF; Recaldin T; Gerard R; Avignon B; Bollen Y; Esposito C; Guja-Jarosz K; Kromer K; Filip A; Aubert J; Schneider A; Bacac M; Bscheider M; Stokar-Regenscheit N; Piscuoglio S; Beumer J; Gjorevski N
Nat Biomed Eng; 2024 Apr; 8(4):345-360. PubMed ID: 38114742
[TBL] [Abstract][Full Text] [Related]
2. Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.
Kroll KT; Mata MM; Homan KA; Micallef V; Carpy A; Hiratsuka K; Morizane R; Moisan A; Gubler M; Walz AC; Marrer-Berger E; Lewis JA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305322120. PubMed ID: 37603766
[TBL] [Abstract][Full Text] [Related]
3. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
4. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
5. Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies.
Chen J; Pan Z; Han L; Liu J; Yue Y; Xiao X; Zhang B; Wu M; Yuan Y; Bian Y; Jiang H; Xie Y; Zhu J
Heliyon; 2023 Jul; 9(7):e17960. PubMed ID: 37456045
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
[No Abstract] [Full Text] [Related]
7. Safety Profiling of Tumor-targeted T Cell-Bispecific Antibodies with Alveolus Lung- and Colon-on-Chip.
Kerns JS; Belgur C; Kanellias M; Manatakis DV; Barrile R; Tien-Street W; Ewart L; Gjorevski N; Cabon L
Bio Protoc; 2023 Jan; 13(1):. PubMed ID: 36789090
[TBL] [Abstract][Full Text] [Related]
8. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM; LaPorte SL; Wong L; White C; Vinod V; Shen J; Yu W; Koditek D; Winter MB; Moore SJ; Mei L; Diep L; Huang Y; Liu S; Vasiljeva O; West J; Richardson J; Irving B; Belvin M; Kavanaugh WM
Cancer Res; 2022 Nov; 82(22):4288-4298. PubMed ID: 36112781
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.
Leclercq G; Servera LA; Danilin S; Challier J; Steinhoff N; Bossen C; Odermatt A; Nicolini V; Umaña P; Klein C; Bacac M; Giusti AM; Schneider A; Haegel H
Oncoimmunology; 2022; 11(1):2039432. PubMed ID: 35186442
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
11. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Sam J; Colombetti S; Fauti T; Roller A; Biehl M; Fahrni L; Nicolini V; Perro M; Nayak T; Bommer E; Schoenle A; Karagianni M; Le Clech M; Steinhoff N; Klein C; Umaña P; Bacac M
Front Oncol; 2020; 10():575737. PubMed ID: 33330050
[TBL] [Abstract][Full Text] [Related]
12. T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ; Zweegman S
Lancet; 2023 Jul; 402(10396):142-158. PubMed ID: 37271153
[TBL] [Abstract][Full Text] [Related]
13. Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.
Kerns SJ; Belgur C; Petropolis D; Kanellias M; Barrile R; Sam J; Weinzierl T; Fauti T; Freimoser-Grundschober A; Eckmann J; Hage C; Geiger M; Ng PR; Tien-Street W; Manatakis DV; Micallef V; Gerard R; Bscheider M; Breous-Nystrom E; Schneider A; Giusti AM; Bertinetti-Lapatki C; Grant HS; Roth AB; Hamilton GA; Singer T; Karalis K; Moisan A; Bruenker P; Klein C; Bacac M; Gjorevski N; Cabon L
Elife; 2021 Aug; 10():. PubMed ID: 34378534
[TBL] [Abstract][Full Text] [Related]
14. γδ T cell-mediated cytotoxicity against patient-derived healthy and cancer cervical organoids.
Dong J; Holthaus D; Peters C; Koster S; Ehsani M; Quevedo-Olmos A; Berger H; Zarobkiewicz M; Mangler M; Gurumurthy RK; Hedemann N; Chumduri C; Kabelitz D; Meyer TF
Front Immunol; 2023; 14():1281646. PubMed ID: 38090581
[TBL] [Abstract][Full Text] [Related]
15. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
16. A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.
Avanzino BC; Prabhakar K; Dalvi P; Hartstein S; Kehm H; Balasubramani A; Boudreau AA; Buelow B; Chang K; Davison LM; Iyer S; Kalwit V; Lewis Wilson K; Malik-Chaudhry HK; Pierson W; Pineda G; Rangaswamy US; Saiganesh S; Schellenberger U; Ugamraj HS; Yabut RD; Buelow R; Chapman J; Trinklein ND; Harris KE
Oncoimmunology; 2022; 11(1):2113697. PubMed ID: 36016696
[TBL] [Abstract][Full Text] [Related]
17. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Haber L; Olson K; Kelly MP; Crawford A; DiLillo DJ; Tavaré R; Ullman E; Mao S; Canova L; Sineshchekova O; Finney J; Pawashe A; Patel S; McKay R; Rizvi S; Damko E; Chiu D; Vazzana K; Ram P; Mohrs K; D'Orvilliers A; Xiao J; Makonnen S; Hickey C; Arnold C; Giurleo J; Chen YP; Thwaites C; Dudgeon D; Bray K; Rafique A; Huang T; Delfino F; Hermann A; Kirshner JR; Retter MW; Babb R; MacDonald D; Chen G; Olson WC; Thurston G; Davis S; Lin JC; Smith E
Sci Rep; 2021 Jul; 11(1):14397. PubMed ID: 34257348
[TBL] [Abstract][Full Text] [Related]
18. Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining
Van De Vyver AJ; Weinzierl T; Eigenmann MJ; Frances N; Herter S; Buser RB; Somandin J; Diggelmann S; Limani F; Lehr T; Bacac M; Walz AC
Mol Cancer Ther; 2021 Feb; 20(2):357-366. PubMed ID: 33298591
[TBL] [Abstract][Full Text] [Related]
19. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M; Colombetti S; Herter S; Sam J; Perro M; Chen S; Bianchi R; Richard M; Schoenle A; Nicolini V; Diggelmann S; Limani F; Schlenker R; Hüsser T; Richter W; Bray-French K; Hinton H; Giusti AM; Freimoser-Grundschober A; Lariviere L; Neumann C; Klein C; Umaña P
Clin Cancer Res; 2018 Oct; 24(19):4785-4797. PubMed ID: 29716920
[No Abstract] [Full Text] [Related]
20. Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Leclercq-Cohen G; Steinhoff N; Albertí Servera L; Nassiri S; Danilin S; Piccione E; Yángüez E; Hüsser T; Herter S; Schmeing S; Gerber P; Schwalie P; Sam J; Briner S; Jenni S; Bianchi R; Biehl M; Cremasco F; Apostolopoulou K; Haegel H; Klein C; Umaña P; Bacac M
Clin Cancer Res; 2023 Nov; 29(21):4449-4463. PubMed ID: 37379429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
